TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06159114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ningmitai capsule
Description: Ningmitai capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ningmitai capsule
Description: Ningmitai capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib capsule
Description: Celecoxib is one of NSAIDs recommended by the CUA Prostatitis Guidelines for alleviating pain symptoms in CP/CPPS patients. The instruction of Celecoxib capsule is 1 capsule at a time, 1 time a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib capsule
Description: Celecoxib is one of NSAIDs recommended by the CUA Prostatitis Guidelines for alleviating pain symptoms in CP/CPPS patients. The instruction of Celecoxib capsule is 1 capsule at a time, 1 time a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ningmitai placebo
Description: Ningmitai placebo, a look-alike substance that contains no active drug, similar to Ningmitai capsule in color, smell, taste, shape, texture and other characteristics, 0.38g/ capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib placebo
Description: Celecoxib placebo, a look-alike substance that contains no active drug, similar to Celecoxib capsule in color, smell, taste, shape, texture and other characteristics, 0.2g/ capsule.
Study: NCT05168956

Intervention type: OTHER
Intervention: Collect data of medical record
Description: Collect data of medical record:~* Genealogy characteristics~* Family characteristics: Number of members in the sibling, rank in the sibling / incestuous relationships or not~* Graphic representation: age / gender / age at time of sexual assault / whether or not a victim of sexual violence / education / family dynamics / living environment during childhood / Criminal category
Study: NCT06646757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HELP
Description: 3) IBD Help Center (HELP) is a resource operated by the Crohn's and Colitis Foundation (CCF) for individuals to connect with an information specialist via email, call, or online live chat at no cost
Study: NCT05218863

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05367973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVR Dose 1
Description: Estradiol 80 ug/day + progesterone 4 mg/day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVR Dose 2
Description: Estradiol 160 ug/day + progesterone 8 mg/day
Study: NCT04749641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Histone H3.3-K27M Neoantigen Vaccine Therapy
Description: The researched vaccine, containing H3.3-K27M-targeting neoantigen peptides and poly ICLC, will be administered through subcutaneous injection into DIPG patients after they complete surgical/stereotactic biopsy and conformal radiotherapy. The day of first vaccine injection is defined as D1 (day 1), and then the injections will be administered on D3, D15, Day 29, Day 57, Day 85 and one injection every 8 weeks thereafter. In order to determine the Maximum Tolerated Dose (MTD) of the vaccine, a 6+3 dose escalation design is applied. There are three doses for the vaccine. Dose 1: 0.5mg peptide + Poly ICLC; Dose 2: 1mg peptide + Poly ICLC; Dose 3: 2mg peptide + Poly ICLC.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Histone H3.3-K27M Neoantigen Vaccine Therapy
Description: The researched vaccine, containing H3.3-K27M-targeting neoantigen peptides and poly ICLC, will be administered through subcutaneous injection into DIPG patients after they complete surgical/stereotactic biopsy and conformal radiotherapy. The day of first vaccine injection is defined as D1 (day 1), and then the injections will be administered on D3, D15, Day 29, Day 57, Day 85 and one injection every 8 weeks thereafter. In order to determine the Maximum Tolerated Dose (MTD) of the vaccine, a 6+3 dose escalation design is applied. There are three doses for the vaccine. Dose 1: 0.5mg peptide + Poly ICLC; Dose 2: 1mg peptide + Poly ICLC; Dose 3: 2mg peptide + Poly ICLC.
Study: NCT06646757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HELP
Description: 3) IBD Help Center (HELP) is a resource operated by the Crohn's and Colitis Foundation (CCF) for individuals to connect with an information specialist via email, call, or online live chat at no cost

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEER
Description: 4) Power of Two (PEER) is a one-on-one peer mentoring program operated by the Crohn's \& Colitis Foundation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEER
Description: 4) Power of Two (PEER) is a one-on-one peer mentoring program operated by the Crohn's \& Colitis Foundation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEER
Description: 4) Power of Two (PEER) is a one-on-one peer mentoring program operated by the Crohn's \& Colitis Foundation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEER
Description: 4) Power of Two (PEER) is a one-on-one peer mentoring program operated by the Crohn's \& Colitis Foundation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEER
Description: 4) Power of Two (PEER) is a one-on-one peer mentoring program operated by the Crohn's \& Colitis Foundation
Study: NCT05924191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Intra-oral irradiations wll be performed with a low intensity Laser device at 4 anatomical points, with a wavelength of 660 nm. The extraoral FBM will be applied with 1 cluster (20cm2) with a wavelength of 630nm. Subsequently, the same region will be irradiated with the same cluster, using the 4 LEDs with a wavelength of 850 nm 1 hour before performing the surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Corticosteroid
Description: Participants will receive 1 hour before the surgery a placebo tablet, with the same physical and organoleptic characteristics, composed of corn starch, without harmful effects on health and simulating Dexamethasone (Celsius Laboratory, Montevideo, Uruguay).).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Simulation Photobiomodulation
Description: The irradiation simulations will be practiced in the same anatomical points described in the experimental group. This protocol will be carried out 1 hour before the surgical procedure (Baseline). The Laser device will be disconnected and its beep sound will be recorded and run on simulating the irradiation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: The patients will receive Dexamethasone 8 mg (Corodex, Laboratorio Celsius, Montevideo, Uruguay) PO 1 hour before surgery (Almeida et al 2019)
Study: NCT06646757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEER
Description: 4) Power of Two (PEER) is a one-on-one peer mentoring program operated by the Crohn's \& Colitis Foundation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEER
Description: 4) Power of Two (PEER) is a one-on-one peer mentoring program operated by the Crohn's \& Colitis Foundation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEER
Description: 4) Power of Two (PEER) is a one-on-one peer mentoring program operated by the Crohn's \& Colitis Foundation
Study: NCT06646354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Rosuvastatin/Candesartan/Amlodipine
Description: PO, QD, 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan/Amlodipine
Description: PO, QD, 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan/Rosuvastatin/Ezetimibe
Description: PO, QD, 8 weeks
Study: NCT06630364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: Induction: Sevoflurane in N2O/O2, Propofol (1-1.5 mg/kg) Analgesia: Ketamine (0.5 mg/kg) Maintenance: Sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: Induction: Sevoflurane in N2O/O2 Analgesia: Propofol (1-1.5 mg/kg), Fentanyl (1 µg/kg) Maintenance: Sevoflurane
Study: NCT06577571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CKM-EMPOWER
Description: CKM-EMPOWER is a series of 11 just-in-time educational videos on topics related to caring for patients who opt for CKM: CKM overview, dysgeusia, fatigue, restless leg syndrome, uremic pruiritis, cramping, pain, volume overload, electrolyte abnormalities, anticipatory grief, and actively dying patient. Videos are approximately 5-10 minutes in length and intended to provide learners with a brief overiew on the definition of each issue, impact of the issue on a patient, assessment of the issue, and approaches to addressing the issue. Videos conclude with references to additional resources on each topic for more in-depth self-study. CKM-EMPOWER was created by a team comprised of a health educator, the principal investigator (nephrologist), a geriatrician and a physician dually trained in nephrology and palliative care and with feedback from a geriatric pharmacist and members of a national professional interest workgroup in kidney palliative care.
Study: NCT05993897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
Description: 10 mg of Dapagliflozin orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhythm control and anticoagulation
Description: In acute stage: Cardioversion with D.C shock if haemodynamically unstable, after failure of pharmacological cardioversion or participant preference.~or pharmacological cardioversion with either IV cordarone in structurally abnormal heart (150mg over 10 minutes followed by1 mg/min infusion for 6 hours followed by 0.5 mg/min not exceeding 2.4 grams over 24 hours till restoration of sinus Rhythm. Then maintenance dose of 200 mg tab orally every 8 hours for 3 weeks then 200 mg tab orally once per day.~or Propafenone (Rytmonorm) 600 mg single oral dose in structurally normal heart then maintenance dose of 150mg tab orally every 8 hours.~+ Rivaroxaban 20mg orally once daily if CHA2DS2 VASc score 1 or more for males and 2 or more for females.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rhythm control and anticoagulation
Description: In acute stage: Cardioversion with D.C shock if haemodynamically unstable, after failure of pharmacological cardioversion or participant preference.~or pharmacological cardioversion with either IV cordarone in structurally abnormal heart (150mg over 10 minutes followed by1 mg/min infusion for 6 hours followed by 0.5 mg/min not exceeding 2.4 grams over 24 hours till restoration of sinus Rhythm. Then maintenance dose of 200 mg tab orally every 8 hours for 3 weeks then 200 mg tab orally once per day.~or Propafenone (Rytmonorm) 600 mg single oral dose in structurally normal heart then maintenance dose of 150mg tab orally every 8 hours.~+ Rivaroxaban 20mg orally once daily if CHA2DS2 VASc score 1 or more for males and 2 or more for females.
Study: NCT06478212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorasidenib
Description: To be taken by mouth once daily in 28-day cycles with no break between cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorasidenib
Description: To be taken by mouth once daily in 28-day cycles with no break between cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: To be taken by mouth once daily for the first 5 days of each 28-day cycle, for a maximum of 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: To be taken by mouth once daily for the first 5 days of each 28-day cycle, for a maximum of 12 cycles
Study: NCT05634044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eNose Device
Description: Participants will place the e-Nose device in their bathroom to record VOCs from the ambient air after they have a bowel movement. In addition to this, all participants will complete 2 blood draws 3 stool collections and questionnaires over the course of 4 visits during a 3-week period.
Study: NCT04876079

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test to induce a decline in plasma glucose
Description: Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to bring plasma glucose to the glycemic threshold. Oral carbohydrates (16g) will be given when plasma glucose levels are at the target threshold. Sixty minutes after carbohydrates consumption, a standardized meal will be provided and participants will be discharged 90 minutes after the meal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test to induce a decline in plasma glucose
Description: Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to bring plasma glucose to the glycemic threshold. Oral carbohydrates (16g) will be given when plasma glucose levels are at the target threshold. Sixty minutes after carbohydrates consumption, a standardized meal will be provided and participants will be discharged 90 minutes after the meal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test to induce a decline in plasma glucose
Description: Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to bring plasma glucose to the glycemic threshold. Oral carbohydrates (16g) will be given when plasma glucose levels are at the target threshold. Sixty minutes after carbohydrates consumption, a standardized meal will be provided and participants will be discharged 90 minutes after the meal.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G6
Description: Participants will have to wear a Dexcom G6 during study interventions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G6
Description: Participants will have to wear a Dexcom G6 during study interventions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G6
Description: Participants will have to wear a Dexcom G6 during study interventions
Study: NCT04833712

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radioablation
Description: Stereotactic Radioablation targets on the pulmonary vein ostium aiming to achieve PVI
Study: NCT04876079

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dex4
Description: When the glycemic threshold is reach, participants will be given 16g of Dex4

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dex4
Description: When the glycemic threshold is reach, participants will be given 16g of Dex4

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dex4
Description: When the glycemic threshold is reach, participants will be given 16g of Dex4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: A subcutaneous insulin bolus will be given to induce a decline in plasma glucose and reach the glycemic threshold.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: A subcutaneous insulin bolus will be given to induce a decline in plasma glucose and reach the glycemic threshold.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: A subcutaneous insulin bolus will be given to induce a decline in plasma glucose and reach the glycemic threshold.
Study: NCT06451809

Intervention type: DEVICE
Intervention: repetitive transcranial magnetic stimulation
Description: rTMS will be applied 5 days out of 7 for 6 weeks, for a total of 30 sessions. The area stimulated will be the left dorsolateral prefrontal cortex, at a frequency of 10 Hz, at 110% of motor threshold for approximately 20 minutes (i.e. 3,000 stimulations per session).
Study: NCT05767684

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccine
Description: Approximately 1.5 x 10\^6±20% cells will be subcutaneously injected to the patient's inguinal area (either left side or right side can be injected, only one area will be injected each time) on day 1, 8, 15, 29, 85, 141, 197, 253 and 309.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccine
Description: Approximately 1.5 x 10\^6±20% cells will be subcutaneously injected to the patient's inguinal area (either left side or right side can be injected, only one area will be injected each time) on day 1, 8, 15, 29, 85, 141, 197, 253 and 309.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 10mg/day on day 43-77

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg on day 43, 57 and 71.
Study: NCT04860518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN beta-1a
Description: Treated daily with IFN beta-1a 10 μg as an IV bolus for 6 days while hospitalised

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Treated daily with dexamethasone 6 mg as an IV bolus for 6 days while hospitalised
Study: NCT05965063

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium M-16V
Description: Bifidobacterium M-16V was dosed at 10 billion colony forming unit (CFU) (equal to 6 drops)/day for 12 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: allergy food avoidance
Description: strict avoidance of the specific allergenic food
Study: NCT05384028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse -led case management
Description: This study would apply case management to the whole course management of AMI patients from admission to 6 months after discharge. Pharmacists, nutritionists, rehabilitation specialists and psychiatrists led by nurse would take the initiative to conduct individualized assessment and health guidance, and case managers would participate in the whole process of inpatient diagnosis and treatment. Coordinating multidisciplinary medical resources to jointly implement diagnosis and treatment and rehabilitation for patients can improve the quality of care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine inpatient care and post-discharge follow-up management
Description: Patients in the control group will receive routine inpatient care and post-discharge follow-up management
Study: NCT05306366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]-Lu AF90103
Description: PET ligand administrated as a single intravenous bolus injection
Study: NCT05921058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secretome
Description: Mesenchymal stem cell secretome obtained from Kalbe Pharma Company

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 0,9% infusion
Study: NCT05383040

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous release
Description: Percutaneous release of A1 pulley release will be performed in the well-managed operation theater set up, using an 18 gauge hypodermic needle, after preparation of the skin and injection of 1ml 2% plain lidocaine. The proper location of the pulley will be defined using surface landmarks in each digit after waiting a few minutes to allow the anesthetic to take effect the 18 gauge needle will be longitudinally moved to keep the level of the needle parallel with the tendon grating sensation will be elucidated confirming the cut of pulley until there is no grating sensation felt and improvement of symptoms. A sterile dressing will be placed.
Study: NCT04897698

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LB001
Description: Probiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: LB001
Description: Probiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LB001
Description: Probiotics
Study: NCT01594697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT04976283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone with (or without) metformin and/or DPP4 inhibitor (no SGLT2 inhibitor). The maximum dose for metformin would be 2.5 g/day, while for pioglitazone would be 45mg/day. The maximum dose for DPP4 inhibitor would be 100mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Empagliflozin with (or without) metformin and/or DPP4 inhibitor (no pioglitazone). The maximum dose for metformin would be 2.5g/day, while for empagliflozin would be 25mg/day depending on follow up blood sugar levels and tolerability. The maximum dose 100mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone + Empagliflozin
Description: Pioglitazone with (or without) metformin and/or DPP4 inhibitor, plus empagliflozin. The maximum dose for metformin would be 2.5g/day; for pioglitazone would be 45mg/day and 25mg/day for empagliflozin, and 100mg daily for DPP4 inhibitors (depending on follow up blood sugar levels and tolerability).
Study: NCT06559098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile coordinated reset (vCR)
Description: Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain
Study: NCT05944133

Intervention type: OTHER
Intervention: No intervention, observational retrospective study
Description: No intervention
Study: NCT04052243

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Invasive exercise testing
Description: Invasive hemodynamic exercise testing
Study: NCT05476627

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers
Description: Blood,urine and imaging biomarkers for early diagnosis and prediction of prognosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers
Description: Blood,urine and imaging biomarkers for early diagnosis and prediction of prognosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers
Description: Blood,urine and imaging biomarkers for early diagnosis and prediction of prognosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers
Description: Blood,urine and imaging biomarkers for early diagnosis and prediction of prognosis.
Study: NCT05331443

Intervention type: DIAGNOSTIC_TEST
Intervention: Reactive hyperemia-peripheral arterial tonometry Index (RHI )
Description: RHI was assessed by RH-PAT using the EndoPAT2000 system .
Study: NCT05717049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline Tablets
Description: 12 week oral treatment